INTRODUCTION
============

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social, communicative, and behavioral deficits. Its clinical manifestations include indifference, communication rejection, language development retardation, and repeated behavioral stereotypes \[[@ref1],[@ref2]\]. ASD comprises different subgroups based on the child's primary symptoms, such as autism, Asperger's syndrome, and other unspecified generalized developmental disorders (Pervasive Developmental Disorder-Not Otherwise Specified) \[[@ref1]\]. In the late 1990s, the prevalence of ASD was less than 60 per 10,000 people, and approximately 30% of the affected individuals were children \[[@ref3]-[@ref5]\]. The incidence of ASD has increased gradually \[[@ref6],[@ref7]\], and the current prevalence is approximately 90−250 per 10,000 individuals \[[@ref8]-[@ref11]\]. Therefore, early detection of ASD is essential for treatment and prevention.

The etiology of autism remains unclear. Previous studies have focused on genetic factors, brain disease, and neurobiological factors, among others. ASD is the result of interaction between genetic and environmental factors \[[@ref12]\]. However, hereditary factor has always been considered to be the dominant factor \[[@ref13],[@ref14]\]. Genetic studies have shown that dizygotic twins have a concordance rate of approximately 31% for ASD. Surprisingly, monozygotic twins with identical DNA only have a concordance rate of approximately 88% for ASD \[[@ref15],[@ref16]\]. Furthermore, findings from twin studies suggest that the prenatal environment can influence the incidence of autism. For instance, Godar and Merrill \[[@ref17]\] proposed that low vitamin D3 levels or viral infection of the uterus can potentially alter the prenatal environment, leading to the development of ASD.

Low serum vitamin D levels are a confirmed environmental risk factor for autism, not only in childhood but also during the fetal period \[[@ref18],[@ref19]\]. Vitamin D plays an important role in the human nervous system and is associated with the prevention of depression \[[@ref20]-[@ref24]\], epilepsy \[[@ref25]-[@ref29]\], schizophrenia \[[@ref30],[@ref31]\], Alzheimer's disease \[[@ref32],[@ref33]\], Parkinson's disease \[[@ref34],[@ref35]\], and multiple sclerosis \[[@ref30],[@ref36]\]. The activated form of vitamin D, that is, 1,25-dihydroxy vitamin D3 (25\[OH\]~2~D~3~), is a steroid with strong endocrine, paracrine, and autocrine effects. It participates in the synthesis of neurotrophic factors and enzymes related to the synthesis of neurotransmitters and in the inhibition of the synthesis of inducible nitric oxide synthase; furthermore, it plays a role in nourishing the nerves and increasing glutathione levels. Therefore, it plays an extensive role in the brain detoxification pathway \[[@ref36]\].

Vitamin D binds to more than 2,700 genes and regulates the expression of more than 200 of these genes \[[@ref37]-[@ref39]\]. It is necessary for regulating serotonin production \[[@ref40]\]. More importantly, vitamin D increases estrogen levels in the placenta and brain \[[@ref41],[@ref42]\]. Estrogen is vital for brain development \[[@ref43]\]; this may explain why males have a four to five times higher risk of autism than females \[[@ref44]\]. Notably, patients with ASD exhibit abnormal regulation of estrogen receptor and estrogen receptor coactivators in the middle frontal gyrus in the brain \[[@ref45]\]. In addition, the combination of *in vivo*, *in vitro*, and animal model data provides a convincing basis for the important role of vitamin D in neuronal cell proliferation, differentiation, neuroprotection, neurotransmitter transmission, and neuroplasticity \[[@ref46],[@ref47]\].

A decade ago, Cannell \[[@ref18]\] first proposed a correlation between vitamin D and ASDs. However, few studies have analyzed symptom improvement in children with ASD after vitamin D supplementation. Therefore, we performed a multicenter meta-analysis to provide further evidence on this.

METHODS
=======

Search Strategy
---------------

This meta-analysis evaluated the association between vitamin D supplementation and symptom improvement in children with autism. Data were collected from the PubMed database, EMBASE, Cochrane Library, Web of Science, Sino-Med, Wanfang Data, and China National Knowledge Infrastructure (CNKI) mainly up to September 2019. The search was conducted using the main terminology. Different search strategies were adopted for different databases. The specific search strategy is presented in [Figures 1](#F1){ref-type="fig"}[](#F2){ref-type="fig"}−[3](#F3){ref-type="fig"}.

Inclusion and Exclusion Criteria
--------------------------------

Inclusion criteria for studies collected for the meta- analysis were as follows: (1) studies on children with ASD diagnosed according to the International Classification of Diseases (ICD-9 and ICD-10) and the Diagnostic Statistical Manual of Mental Disorders (DSM-4 and DSM-5); (2) studies including children aged ≤ 18 years; (3) studies in which specific serum vitamin D levels were directly investigated; (4) studies reporting significant differences in vitamin D levels after intervention; (5) studies in which vitamin D supplementation was the intervention; and (6) studies which were randomized controlled trials.

Exclusion criteria were as follows: (1) studies with participants having any disease that could affect serum vitamin D levels and (2) the article type being a meta-analysis, observational study, review study, letter to the editor, or case report.

Data Extraction and Quality Assessment
--------------------------------------

The title, abstract, and full text of studies were independently screened by two researchers. Unrelated studies were excluded. Specific screening procedures are described in the "Description of studies" in the result section. Any disagreement between the two screening researchers was resolved through discussion between them or through evaluation by a third reviewer to reach a final decision. The reasons for exclusion of articles were recorded. The data collected from the relevant studies included the following: (1) general information: first author, publication year, research country, study design, and sample size; (2) specific intervention: the dose and duration of vitamin D supplementation; (3) precise data: the mean and standard deviation values as well as the related p values of vitamin D levels and outcome scores on score sheet, among others. In total, three studies were included in this meta-analysis. The Cochrane bias test was used to evaluate randomized controlled trials (RCTs).

Statistical Analysis
--------------------

The outcomes were analyzed using the Review Manager version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Considering that data to be analyzed in this study have different units, data on 25(OH) D levels and Social Responsiveness Scale (SRS) and Child Autism Rating Scale (CARS) scores were analyzed using the standardized mean difference (SMD) with 95% confidence interval (CI). Statistical heterogeneity was quantified using Q test and *I* ^2^ statistic. Significant heterogeneity was suggested as *p* \< 0.10 or *I* ^2^ \> 50%. If *p* \> 0.1 and/or *I* ^2^ \< 50%, the fixed effects model was used to test the combined effect; otherwise, the random effects model was adopted.

RESULTS
=======

Description of Studies
----------------------

In total, 452 studies were retrieved after searching the databases and other ways (contact the author or check out newspapers and magazines) mainly up to September 2019. Of the 452 studies, 264 were from PubMed, with the filter of humans; 130 from Web of Science, 19 from EMBASE, 17 from Cochrane Library, 6 from Wanfang data, 14 from CNKI, and 2 from Sino-Med. Following the elimination of 37 duplicated articles, 33 articles were obtained by initial screening of the title and abstract. After browsing the full text, 29 articles (case-control study \[n = 12\], multiple research objects \[n = 6\], mixed intervention \[n = 4\], open-label trial \[n = 4\], no ending data \[n = 2\], and inappropriate inclusion criteria \[n = 1\]). Notably, one of the articles \[[@ref48]\], both in terms of research design and final analysis, was tremendously consistent with this meta-analysis. However, the included children with autism had serum vitamin D levels \< 30 ng/ml, which was inconsistent with the inclusion criteria of the present study; therefore, it was excluded. After full text screening, four RCT articles met the inclusion criteria; however, among them, the article of Saad *et al*. \[[@ref49]\] was retracted because the validity of the research results was not demonstrated \[[@ref50],[@ref51]\]. Ultimately, three RCTs were included in the analysis. [Figure 4](#F4){ref-type="fig"} presents the selection process. In this meta-analysis, all data relevant to vitamin D and ASD were extracted; the extracted data included sample size, age, sex, serum vitamin D levels, vitamin D supplement dose and duration, and outcome indicators. The basic characteristics of the included studies are shown in [Table 1](#T1){ref-type="table"}.

Serum Vitamin D Levels
----------------------

Baseline serum vitamin D levels of both the experimental and control groups in the three studies included in this meta-analysis were recorded. We only selected the data on vitamin D group and placebo group, neglecting unrelated information such as that on omega-3 group and vitamin D ＋ omega-3 group, in the studies of Fang *et al*. \[[@ref52]\] and Mazahery *et al*. \[[@ref53],[@ref54]\]. Results showed that there were no significant differences in baseline serum vitamin D levels between the experimental and control groups in the three included studies (SMD = 0.3, 95% CI = −0.06 to 0.65; *p* = 0.1), and low heterogeneity was noted among the three studies (*I*^2^ = 0%) ([Fig. 5](#F5){ref-type="fig"}).

Outcome Scores on Score Sheet
-----------------------------

Two of the three articles used the Aberrant Behavior Checklist (ABC) and SRS scale scores as outcome indicators, whereas the other article used the CARS score as the indicator. The scores on these three evaluation scales can comprehensively represent the severity degree of symptoms in children with ASD. Among these three scales, evaluation indexes partially coincide with each other, and SRS and CARS scores are assigned in the same way, which is rather different from that for the ABC scale. Furthermore, the CARS score before the trial was not recorded in Fang's article \[[@ref52]\]. Therefore, SRS and CARS scores after vitamin D supplementation were used as the outcome index in the present study.

The fixed effects model was used because there was no heterogeneity between CARS and SRS scores (c^2^ = 1.7, df = 2, *I* ^2^ = 0%; *p* = 0.43). The results showed that the total effect amount fell on the left side of the invalid line, and test group intervention was considered favorable. Additionally, the mean vitamin D level was higher in the test group than in the placebo group. Thus, vitamin D supplementation was found to be a favorable factor for symptom improvement in children with autism (SMD = −0.46, 95% CI: −0.87 to −0.05; *p* = 0.03; [Fig. 6](#F6){ref-type="fig"}).

Publication Bias
----------------

Demographic information and additional details extracted from the included studies are summarized in [Table 1](#T1){ref-type="table"}. The Cochrane Handbook for Systematic Reviews of Interventions was used to evaluate the studies, except two studies: Kerley's study \[[@ref55]\], which did not describe the randomization algorithm, and Fang's analysis \[[@ref52]\], which did not describe the specific process and may have had other biases. Most studies qualified by meeting the following requirements: (1) provided clear inclusion and exclusion criteria, (2) proposed a randomization methodology, (3) stated allocation concealment, (4) used a double-blind approach in all RCT groups, and (5) demonstrated complete outcome data ([Figs. 7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}).

Sensitivity Analyses
--------------------

Sensitivity analysis of baseline serum vitamin D levels was performed by reanalyzing the remaining literature after removing references one by one. Same result was obtained for each analysis. No heterogeneity was observed, and the total benefit was intersected with the invalid line. In the sensitivity analyses for the scores, the outcome indicators, the same method was followed, and it was found that the heterogeneity remained unchanged. Although some results showed that the total effect amount intersected the invalid line, most of the total effect amounts consistently fell on the left side of the invalid line. Together, these two similar findings indicate that the results of this meta-analysis had a relatively low sensitivity and the total performance was reliable.

Publishing Bias
---------------

According to the recommendations of the Cochrane Handbook, if a funnel chart is used for publication bias evaluation, the number of studies included in the index should not be less than 10. Otherwise, considerably few studies will be included in the index, leading to a decline in the inspection ability of the funnel chart; thus, the authenticity of the asymmetry would not be judged. The research indicators of this study did not reach 10 articles; hence, no funnel plot analysis of publication bias was performed.

DISCUSSION
==========

This study is the first meta-analysis to explore the effect of vitamin D supplementation on children with ASD. We conducted a meta-analysis of three RCTs including 203 children with ASD who were assigned to receive either vitamin D supplementation or a placebo. The results suggest that appropriate vitamin D supplementation is beneficial for symptom improvement in children with ASD, as demonstrated by reduced SRS and CARS scores.

Previous studies do not provide clear evidence to prove that vitamin D supplementation can result in symptom improvement in children wish ASD. However, our results are supported by the finding of a significant number of researchers who have reported that low serum vitamin D levels are a risk factor for ASD both in the fetal life and during childhood.

Two series of articles \[[@ref56],[@ref57]\] revealed that serum vitamin D levels in children with ASD were significantly lower than those in healthy children, and a significant correlation was found between these levels and various core symptoms of ASD. Saad *et al*. \[[@ref39]\] concluded that among 122 children with ASD, 57% had vitamin D insufficiency and 30% had vitamin D deficiency; meanwhile, 80.72% children were treated with vitamin D3, resulting in dramatic improvement. Coincidentally, other related studies \[[@ref58]-[@ref63]\] have also reached the same conclusion, that is, serum vitamin D levels in children with autism are significantly lower than those in control group. Moreover, the study of Mostafa and Al-Ayadhi \[[@ref60]\] found a negative association between autism severity and serum vitamin D levels.

Adams *et al*. \[[@ref64],[@ref65]\] found that nutritional and metabolic statuses of children with autism improved after supplementation with vitamins and minerals in their daily diet. In an year-long study, Infante *et al*. \[[@ref66]\] suggested that a combination of omega-3 and vitamin D supplementation could effectively improve the core symptoms in children with autism. Saad *et al*. \[[@ref49]\] found a significant symptom improvement after appropriate vitamin D supplementation in children with autism. However, Kerley *et al*. \[[@ref67]\] found that when children with autism and those with asthma received the same dose of vitamin D simultaneously, the increase in serum 25(OH)D levels in children with autism remained significantly smaller than that in children with asthma in the control group even after being supplemented for a longer duration.

Studies \[[@ref68]-[@ref71]\] have also emphasized that lack of vitamin D during pregnancy is associated with autism after birth. Stubbs *et al*. \[[@ref71]\] conducted a study on mothers of children with autism; the mothers received vitamin D supplementation during pregnancy, and the babies received it during neonatal period. The results showed that autism developed in 1 in 19 cases (5%); the occurrence rate was clearly lower than the theoretical reported rate of 20% \[[@ref72]\].

Through the considerable research mentioned above, we observed the same phenomenon, that is, children with autism have lower serum vitamin D levels than normal children.

Such observation prompted us to complete this research. Before conducting this study, only few case-control studies and one meta-analysis were available to provide strong evidence regarding this observation. Wang *et al*. \[[@ref61]\] conducted a meta-analysis and screened 11 case-control studies, obtaining 870 patients with autism and 782 healthy controls; they concluded that patients with autism had lower serum vitamin D levels than the healthy control group patients. However, this is only an observational study with insufficient argument and no mention of the topic we are concerned with.

Low serum vitamin D levels in children with ASD may be due to insufficient intaken and an increased consumption. Some children with ASD may have other diseases that possibly affect vitamin D absorption and transformation in the body. Additionally, geographical reasons and living habits associated with insufficient exposure to sunlight may hinder vitamin D absorption. Vitamin D is extremely important for human nervous system. It aids in the synthesis of neurotrophic factors and enzymes, nourishment of the nerves, secretion of neurotransmitters, and fusion and regulation of gene expression, among others \[[@ref46],[@ref47]\]. Therefore, a proper dose of vitamin D supplements may play a beneficial role in the development of the nervous system, thereby improving the symptoms of autism. These insights are merely reasonable speculations, and more research is needed to confirm this conclusion.

In the analysis of baseline serum vitamin D levels, the obtained result intersected with the ineffective line; the difference in the baseline levels was not significant, and the study was comparable. Under this premise, the difference in SRS and CARS scores after vitamin D supplementation both in the experimental and control groups was taken as the indicator. The results showed that the diamond fell on the left side of the invalid line. Furthermore, the studied factors are beneficial to the occurrence of the outcome, implying that vitamin D supplementation is a protective factor for children with ASD.

Regarding sensitivity analysis, the total effect amount was consistent with the current result, but in some results, the total effect amount intersected with the invalid line. In any case, each analysis result showed that the majority of the total effect amount fell on the left side of the invalid line. It means that vitamin D supplementation is absolutely harmless to children with autism and may have a certain improvement effect.

However, this meta-analysis is limited by the number and level of existing clinical trials. The authors' level and objective conditions are also limited, and the search scope makes it difficult to cover all relevant literature, thereby reducing the intensity of the research demonstration to some extent. Thus, more favorable evidence remains to be confirmed by conducting more high-quality, large-sample clinical trials or meta-analysis in the future.
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###### 

The basic characteristics of the studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                           Operation country   Study design   Sample size     Age (in years)      Sex (male%)     Baseline 25(OH)D levels   Autism criteria   Intervention                                                                 Outcome evaluation
  ----------------------------------------------- ------------------- -------------- --------------- ------------------- --------------- ------------------------- ----------------- ---------------------------------------------------------------------------- --------------------
  Fang *et al*., 2018 \[[@ref52]\]                China               RCT            Vd: 12\         Vd: 10 ± 2\         Vd: 67\         Vd: 32 ± 10\              DSM-5             Vd: 800 U of vitamin D3/day for 12 months\                                   CARS
                                                                                     OM: 12\         OM: 10 ± 2\         OM: 50\         OM: 29 ± 12\                                OM: 900 mg of omega-3/day for 12 months\                                     
                                                                                     Vd ＋ OM: 12\   Vd ＋ OM: 10 ± 3\   Vd ＋ OM: 58\   Vd ＋ OM: 30 ± 10\                          Vd ＋ OM: 800 U of vitamin D3/day and 900 mg of omega-3/day for 12 months\   
                                                                                     Pl: 12          Pl: 10 ± 3          Pl: 58          Pl: 28 ± 10 (ng/ml)                         Pl: placebo for 12 months                                                    

  Mazahery *et al*., 2019 \[[@ref53],[@ref54]\]   New Zealand         RCT            Vd: 31\         Vd: 5 ± 2\          Vd: 84\         Vd: 63 ± 27\              DSM-5             Vd: 2,000 IU of vitamin D3/day for 12 months\                                ABC\
                                                                                     OM: 29\         OM: 5 ± 2\          OM: 78\         OM: 60 ± 25\                                N3: 722 mg of DHA/day for 12 months\                                         SRS
                                                                                     Vd ＋ OM: 28\   Vd ＋ OM: 5 ± 1\    Vd ＋ OM: 87\   Vd ＋ OM: 56 ± 26\                          Vd ＋ N3: 2,000 IU of vitamin D3 plus 722 mg of DHA/day for 12 months\       
                                                                                     Pl: 29          Pl: 6 ± 1           Pl: 81          Pl: 56 ± 27 (nmol/L)                        Pl: placebo for 12 months                                                    

  Kerley *et al*., 2017 \[[@ref55]\]              Ireland             RCT            T: 18\          T: 8 ± 23\          T: 15\          T: 58 ± 18\               DSM/ADOS          T: 2,000 IU of vitamin D3/day for 20 weeks\                                  ABC\
                                                                                     C: 20           C: 7 ± 4            C: 18           C: 52 ± 20 (nmol/L)                         C: placebo for 20 weeks                                                      SRS\
                                                                                                                                                                                                                                                                  DD-CGAS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT, randomized controlled trials; Vd, vitamin D group; OM, omega-3 group; Vd ＋ OM, vitamin D ＋ omega-3 group; Pl, placebo group; T, test group; C, control group; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; ADOS, Autism Diagnostic Observation Schedule; CARS, Childhood Autism Rating Scale; ABC, Aberrant behavior checklist; SRS, Social Responsiveness Scale; DD-CGAS, The Developmental Disabilities-Children's Global Assessment Scale.

[^1]: These authors contributed equally to this study as co-first authors.
